Free Trial
→ Musk’s Project Colossus could mint millionaires (From Brownstone Research) (Ad) Buy CLDX Stock  Free CLDX Stock Alerts

Celldex Therapeutics (CLDX) Financials

Celldex Therapeutics logo
$20.49 -0.42 (-2.01%)
Closing price 05/20/2025 04:00 PM Eastern
Extended Trading
$20.49 0.00 (0.00%)
As of 08:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Celldex Therapeutics

Annual Income Statements for Celldex Therapeutics

This table shows Celldex Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Income / (Loss) Attributable to Common Shareholders		 -158 -141 -112 -71 -60 -51 -151 -93 -129 -127 -118
Consolidated Net Income / (Loss)		 -158 -141 -112 -71 -60 -51 -151 -93 -129 -127 -118
Net Income / (Loss) Continuing Operations		 -158 -141 -112 -71 -60 -51 -151 -93 -129 -127 -118
Total Pre-Tax Income 		-158 -141 -112 -71 -61 -51 -152 -117 -129 -127 -118
Total Operating Income		 -195 -155 -115 -71 -63 -55 -156 -122 -133 -130 -122
Total Gross Profit		 7.02 6.88 2.36 4.65 7.42 3.57 9.54 13 6.79 5.48 3.59
Total Revenue		 7.02 6.88 2.36 4.65 7.42 3.57 9.54 13 6.79 5.48 3.59
Operating Revenue		 7.02 6.88 2.36 4.65 7.42 3.57 9.54 13 6.79 5.48 3.59
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 202 161 118 76 71 59 166 134 140 135 126
Selling, General & Admin Expense		 39 31 27 20 14 15 19 25 36 34 21
Research & Development Expense		 164 118 82 53 43 43 66 96 103 100 104
Other Operating Expenses / (Income)		 0.00 0.00 -6.86 -1.41 -4.22 -1.29 -30 -0.80 - - -
Other Special Charges / (Income)		 0.00 13 15 0.00 0.00 - - - - - -
Total Other Income / (Expense), net		 37 13 2.91 0.51 2.41 4.15 4.49 4.21 4.39 2.34 4.35
Interest & Investment Income		 37 13 2.91 0.51 2.41 4.15 4.49 4.21 4.39 2.34 4.35
Basic Earnings per Share		 ($2.45) ($2.92) ($2.40) ($1.64) ($2.02) ($3.51) ($14.48) ($10.86) ($18.99) ($1.31) ($1.32)
Weighted Average Basic Shares Outstanding		 64.40M 48.45M 46.89M 42.87M 29.64M 14.51M 10.44M 8.57M 6.77M 97.05M 89.40M
Diluted Earnings per Share		 ($2.45) ($2.92) ($2.40) ($1.64) ($2.02) ($3.51) ($14.48) ($10.86) ($18.99) ($1.31) ($1.32)
Weighted Average Diluted Shares Outstanding		 64.40M 48.45M 46.89M 42.87M 29.64M 14.51M 10.44M 8.57M 6.77M 97.05M 89.40M
Weighted Average Basic & Diluted Shares Outstanding		 66.38M 55.90M 47.21M 46.74M 29.64M 14.51M 10.44M 8.57M 6.77M 97.05M 89.40M

Quarterly Income Statements for Celldex Therapeutics

This table shows Celldex Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -54 -47 -42 -36 -33 -43 -38 -31 -29 -26 -27
Consolidated Net Income / (Loss)		 -54 -47 -42 -36 -33 -43 -38 -31 -29 -26 -27
Net Income / (Loss) Continuing Operations		 -54 -47 -42 -36 -33 -43 -38 -31 -29 -26 -27
Total Pre-Tax Income 		-54 -158 0.00 0.00 0.00 -141 0.00 0.00 0.00 -86 -27
Total Operating Income		 -63 -56 -52 -46 -41 -48 -41 -33 -32 -28 -28
Total Gross Profit		 0.70 1.18 3.19 2.50 0.16 4.13 1.52 0.27 0.97 1.61 0.41
Total Revenue		 0.70 1.18 3.19 2.50 0.16 4.13 1.52 0.27 0.97 1.61 0.41
Operating Revenue		 0.70 1.18 3.19 2.50 0.16 4.13 1.52 0.27 0.97 1.61 0.41
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 63 57 55 49 41 52 43 33 33 29 28
Selling, General & Admin Expense		 11 10 10 9.13 9.10 8.83 8.22 7.22 6.64 6.60 6.53
Research & Development Expense		 53 47 45 40 32 30 35 26 27 23 22
Total Other Income / (Expense), net		 8.94 8.94 10 10 7.80 4.32 2.98 2.70 3.11 1.40 0.91
Interest & Investment Income		 8.94 8.94 10 10 7.80 4.32 2.98 2.70 3.11 1.40 0.91
Basic Earnings per Share		 ($0.81) ($0.71) ($0.64) ($0.54) ($0.56) ($0.84) ($0.81) ($0.65) ($0.62) ($0.57) ($0.57)
Weighted Average Basic Shares Outstanding		 66.38M 64.40M 66.29M 66.02M 58.87M 48.45M 47.26M 47.25M 47.21M 46.89M 46.92M
Diluted Earnings per Share		 ($0.81) ($0.71) ($0.64) ($0.54) ($0.56) ($0.84) ($0.81) ($0.65) ($0.62) ($0.57) ($0.57)
Weighted Average Diluted Shares Outstanding		 66.38M 64.40M 66.29M 66.02M 58.87M 48.45M 47.26M 47.25M 47.21M 46.89M 46.92M
Weighted Average Basic & Diluted Shares Outstanding		 66.39M 66.38M 66.34M 66.29M 65.91M 55.90M 47.26M 47.26M 47.25M 47.21M 47.10M

Annual Cash Flow Statements for Celldex Therapeutics

This table details how cash moves in and out of Celldex Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Change in Cash & Equivalents		 -6.46 5.39 -9.71 -4.69 33 -13 -16 -2.17 -30 44 -141
Net Cash From Operating Activities		 -158 -107 -104 -61 -40 -46 -75 -100 -113 -99 -102
Net Cash From Continuing Operating Activities		 -158 -107 -104 -61 -40 -46 -75 -100 -113 -99 -102
Net Income / (Loss) Continuing Operations		 -158 -141 -112 -71 -60 -51 -151 -93 -129 -127 -118
Consolidated Net Income / (Loss)		 -158 -141 -112 -71 -60 -51 -151 -93 -129 -127 -118
Depreciation Expense		 3.18 3.01 2.90 3.07 3.93 4.86 3.58 4.41 3.10 3.00 2.39
Amortization Expense		 -16 -6.22 0.84 -3.21 -0.73 -1.14 -0.82 1.19 3.56 1.65 1.18
Non-Cash Adjustments To Reconcile Net Income		 34 24 16 12 21 5.07 89 0.98 15 13 6.85
Changes in Operating Assets and Liabilities, net		 -22 13 -11 -2.46 -4.52 -4.32 -15 -13 -6.56 11 6.13
Net Cash From Investing Activities		 -290 -106 90 -216 -98 17 30 46 69 -50 -41
Net Cash From Continuing Investing Activities		 -290 -106 90 -216 -98 17 30 46 69 -50 -41
Purchase of Property, Plant & Equipment		 -1.92 -1.82 -1.83 -1.25 -1.55 -0.73 -0.81 -1.79 -2.75 -4.88 -1.93
Purchase of Investments		 -790 -425 -189 -390 -220 -95 -171 -171 -176 -206 -148
Sale of Property, Plant & Equipment		 0.00 0.00 0.07 0.03 0.06 0.02 0.34 - - - -
Sale and/or Maturity of Investments		 502 321 281 175 124 113 201 219 243 161 109
Other Investing Activities, net		 -0.03 -0.08 -0.11 -0.29 - - - - - - -
Net Cash From Financing Activities		 441 218 4.08 272 171 16 29 51 14 193 1.17
Net Cash From Continuing Financing Activities		 441 218 4.08 272 171 16 29 51 14 193 1.17
Issuance of Common Equity		 441 218 4.08 272 171 16 29 51 14 193 1.17

Quarterly Cash Flow Statements for Celldex Therapeutics

This table details how cash moves in and out of Celldex Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -11 -8.04 -6.34 -72 80 14 -7.09 -26 25 11 -9.82
Net Cash From Operating Activities		 -54 -32 -55 -29 -41 -33 -19 -27 -29 -22 -35
Net Cash From Continuing Operating Activities		 -54 -32 -55 -29 -41 -33 -19 -27 -29 -22 -35
Net Income / (Loss) Continuing Operations		 -54 -47 -42 -36 -33 -43 -38 -31 -29 -26 -27
Consolidated Net Income / (Loss)		 -54 -47 -42 -36 -33 -43 -38 -31 -29 -26 -27
Depreciation Expense		 0.87 0.82 0.79 0.80 0.78 0.76 0.77 0.76 0.73 0.67 0.67
Amortization Expense		 -2.27 -3.36 -4.33 -4.74 -3.31 -2.18 -1.63 -1.16 -1.26 -0.52 0.06
Non-Cash Adjustments To Reconcile Net Income		 9.32 9.78 9.62 7.64 7.21 7.21 7.12 5.22 4.34 4.51 -11
Changes in Operating Assets and Liabilities, net		 -8.50 7.38 -19 2.82 -13 4.98 13 -1.51 -3.02 0.07 1.42
Net Cash From Investing Activities		 43 24 48 -47 -315 -171 12 1.16 53 31 23
Net Cash From Continuing Investing Activities		 43 24 48 -47 -315 -171 11 1.25 52 31 23
Purchase of Property, Plant & Equipment		 -0.27 -0.76 -0.55 -0.27 -0.34 -0.67 -0.16 -0.41 -0.59 -0.24 -0.35
Purchase of Investments		 -152 -129 -100 -169 -392 -241 -28 -82 -74 -56 -63
Sale and/or Maturity of Investments		 195 154 148 122 77 71 40 83 127 88 86
Net Cash From Financing Activities		 0.20 0.39 1.24 3.71 436 217 0.26 0.13 0.69 1.40 2.31
Net Cash From Continuing Financing Activities		 0.20 0.39 1.24 3.71 436 217 0.26 0.13 0.69 1.40 2.31
Issuance of Common Equity		 0.20 0.39 1.24 3.71 436 217 0.26 0.13 0.69 1.40 2.31

Annual Balance Sheets for Celldex Therapeutics

This table presents Celldex Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Total Assets		 792 466 353 445 236 123 156 316 383 338 248
Total Current Assets		 747 432 318 411 198 67 99 145 196 295 205
Cash & Equivalents		 28 35 29 39 44 11 24 40 42 72 28
Short-Term Investments		 697 389 276 369 151 53 70 99 147 218 173
Accounts Receivable		 0.70 2.63 0.35 0.17 1.80 1.02 3.16 1.88 1.78 0.97 0.43
Prepaid Expenses		 21 5.47 12 2.42 1.62 1.30 1.90 3.45 4.01 4.08 3.52
Plant, Property, & Equipment, net		 4.35 4.06 3.75 3.55 3.82 4.03 6.11 10 13 11 11
Total Noncurrent Assets		 41 30 31 30 34 52 51 160 175 31 32
Intangible Assets		 27 27 27 27 31 49 49 68 81 21 22
Other Noncurrent Operating Assets		 14 2.68 4.11 3.07 3.49 3.51 1.93 1.93 2.13 1.43 1.72
Total Liabilities & Shareholders' Equity		 792 466 353 445 236 123 156 316 383 338 248
Total Liabilities		 45 36 27 25 26 29 32 79 118 47 36
Total Current Liabilities		 40 31 19 17 14 12 13 28 35 30 24
Accounts Payable		 3.27 3.49 3.34 1.23 1.05 1.17 1.07 1.72 1.74 1.51 2.60
Accrued Expenses		 34 22 13 12 8.46 6.50 7.01 19 29 24 19
Other Current Liabilities		 2.39 5.60 2.44 3.30 4.70 3.97 4.53 6.57 4.83 4.42 2.59
Total Noncurrent Liabilities		 5.83 5.33 7.92 8.65 12 17 19 52 83 17 12
Other Noncurrent Operating Liabilities		 5.83 5.33 7.92 8.65 12 17 19 52 83 17 12
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 747 429 326 419 209 94 124 236 265 290 212
Total Preferred & Common Equity		 747 429 326 419 209 94 124 236 265 290 212
Preferred Stock		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 747 429 326 419 209 94 124 236 265 290 212
Common Stock		 2,299 1,823 1,581 1,561 1,280 1,105 1,084 1,046 982 879 673
Retained Earnings		 -1,555 -1,397 -1,256 -1,144 -1,073 -1,013 -962 -813 -719 -591 -464
Accumulated Other Comprehensive Income / (Loss)		 3.31 3.31 1.26 1.89 2.59 2.62 2.58 2.56 2.54 2.31 2.59

Quarterly Balance Sheets for Celldex Therapeutics

This table presents Celldex Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 739 823 846 869 280 299 325 369
Total Current Assets		 694 779 812 835 246 265 290 335
Cash & Equivalents		 17 36 43 115 21 28 54 19
Short-Term Investments		 656 720 760 709 214 224 224 305
Accounts Receivable		 1.06 0.85 1.53 2.67 0.25 0.12 1.31 0.19
Prepaid Expenses		 19 22 8.12 8.81 10 12 9.90 11
Plant, Property, & Equipment, net		 4.60 4.23 3.86 4.06 4.16 3.94 4.00 3.75
Total Noncurrent Assets		 41 40 30 29 30 31 31 31
Intangible Assets		 27 27 27 27 27 27 27 27
Other Noncurrent Operating Assets		 14 13 2.56 2.27 2.97 3.36 3.74 3.68
Total Liabilities & Shareholders' Equity		 739 823 846 869 280 299 325 369
Total Liabilities		 36 37 32 30 34 22 22 24
Total Current Liabilities		 32 32 28 26 28 16 15 16
Accounts Payable		 3.41 1.11 3.80 3.23 3.59 0.88 3.37 2.27
Accrued Expenses		 25 28 19 18 18 12 9.37 11
Other Current Liabilities		 3.15 2.78 5.26 5.52 5.78 2.51 2.47 2.59
Total Noncurrent Liabilities		 4.47 5.18 4.27 3.94 5.70 6.13 6.56 7.52
Other Noncurrent Operating Liabilities		 4.47 5.18 4.27 3.94 5.70 6.13 6.56 7.52
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 703 786 814 839 247 278 303 345
Total Preferred & Common Equity		 703 786 814 839 247 278 303 345
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 703 786 814 839 247 278 303 345
Common Stock		 2,308 2,289 2,278 2,267 1,599 1,591 1,586 1,575
Retained Earnings		 -1,609 -1,508 -1,466 -1,430 -1,354 -1,316 -1,285 -1,229
Accumulated Other Comprehensive Income / (Loss)		 3.57 5.29 1.78 2.24 2.14 2.07 2.12 -0.11

Annual Metrics And Ratios for Celldex Therapeutics

This table displays calculated financial ratios and metrics derived from Celldex Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 1.99% 192.02% -49.32% -37.30% 107.61% -62.54% -25.15% 87.78% 23.83% 52.82% -12.77%
EBITDA Growth		 -31.63% -41.49% -56.19% -18.67% -17.23% 66.61% -32.57% 8.18% -1.10% -5.07% -49.01%
EBIT Growth		 -26.23% -34.11% -61.75% -12.45% -15.12% 64.82% -28.73% 8.57% -2.61% -5.81% -50.33%
NOPAT Growth		 -26.23% -34.11% -61.75% -12.45% -15.12% 64.82% -28.73% 8.57% -2.61% -5.81% -50.33%
Net Income Growth		 -11.62% -25.91% -59.30% -17.95% -17.50% 66.35% -62.51% 27.62% -1.05% -7.72% -44.79%
EPS Growth		 16.10% -21.67% -46.34% 18.81% 42.45% 75.76% -62.51% 27.62% -1.05% 0.76% -29.41%
Operating Cash Flow Growth		 -47.06% -3.43% -70.31% -50.75% 12.95% 38.31% 24.71% 11.59% -14.31% 2.61% -50.05%
Free Cash Flow Firm Growth		 -65.09% -2.00% -96.46% -55.74% 22.26% 10.50% 59.94% 36.87% -109.87% -0.97% -56.91%
Invested Capital Growth		 289.81% -73.78% 89.31% -24.83% -49.62% -1.32% -69.01% 28.14% 34,925.46% -97.97% -36.85%
Revenue Q/Q Growth		 -29.63% 57.69% 118.85% -42.61% 64.15% -19.74% -15.05% 14.17% 1.25% 6.06% 31.40%
EBITDA Q/Q Growth		 -4.81% -15.62% -8.12% 6.51% -20.83% -4.44% 7.26% 6.56% -0.43% -0.94% -7.96%
EBIT Q/Q Growth		 -4.50% -14.65% -7.01% 5.87% -22.87% -1.60% 7.89% 7.13% -1.08% -1.08% -8.83%
NOPAT Q/Q Growth		 -4.50% -14.65% -7.01% 5.87% -22.87% -1.60% 7.89% 7.13% -1.08% -1.08% -8.83%
Net Income Q/Q Growth		 -2.46% -13.50% -5.98% 2.42% -23.70% -2.10% -3.82% 23.43% 0.29% -0.68% -9.01%
EPS Q/Q Growth		 5.04% -10.19% -6.19% -3.14% -64.23% -7.67% -3.82% 23.43% 0.29% 2.24% -8.20%
Operating Cash Flow Q/Q Growth		 0.04% -11.16% -7.50% -18.05% 12.53% 8.71% 5.16% 0.82% -6.20% 7.89% -7.70%
Free Cash Flow Firm Q/Q Growth		 -2.34% -10.40% -8.35% -27.45% 22.03% 13.07% 32.14% 31.99% -83.37% 9.22% -7.61%
Invested Capital Q/Q Growth		 -27.36% -50.99% -3.16% -17.60% -50.84% 4.15% 33.41% 23.30% 446.48% -98.46% -30.58%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -2,957.98% -2,291.97% -4,730.34% -1,534.81% -810.92% -1,436.13% -1,611.27% -909.73% -1,860.60% -2,279.05% -3,314.61%
Operating Margin		 -2,778.89% -2,245.27% -4,889.01% -1,531.78% -854.06% -1,540.19% -1,640.13% -953.68% -1,958.68% -2,363.89% -3,414.11%
EBIT Margin		 -2,778.89% -2,245.27% -4,889.01% -1,531.78% -854.06% -1,540.19% -1,640.13% -953.68% -1,958.68% -2,363.89% -3,414.11%
Profit (Net Income) Margin		 -2,248.76% -2,054.76% -4,765.59% -1,516.04% -805.88% -1,423.96% -1,585.07% -730.06% -1,894.05% -2,321.11% -3,292.81%
Tax Burden Percent		 100.00% 100.00% 100.00% 99.68% 98.09% 100.00% 99.50% 79.30% 100.00% 100.00% 100.00%
Interest Burden Percent		 80.92% 91.51% 97.48% 99.29% 96.20% 92.45% 97.13% 96.53% 96.70% 98.19% 96.45%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1,000.51% -806.56% -496.73% -381.26% -198.97% -129.09% -172.48% -98.58% -245.26% -1,674.12% -624.89%
ROIC Less NNEP Spread (ROIC-NNEP)		 -996.80% -797.43% -487.85% -374.41% -187.04% -113.49% -136.77% -93.74% -230.46% -1,659.24% -612.05%
Return on Net Nonoperating Assets (RNNOA)		 973.67% 769.11% 466.60% 358.83% 159.56% 82.43% 88.59% 61.50% 198.99% 1,623.42% 580.46%
Return on Equity (ROE)		 -26.84% -37.45% -30.13% -22.43% -39.41% -46.66% -83.89% -37.08% -46.27% -50.70% -44.44%
Cash Return on Invested Capital (CROIC)		 -1,118.85% -689.66% -558.47% -352.90% -132.98% -127.77% -67.10% -123.24% -444.12% -1,482.10% -579.72%
Operating Return on Assets (OROA)		 -31.01% -37.77% -28.90% -20.94% -35.32% -39.49% -66.37% -34.77% -36.87% -44.24% -41.15%
Return on Assets (ROA)		 -25.10% -34.56% -28.17% -20.72% -33.32% -36.51% -64.14% -26.62% -35.66% -43.44% -39.68%
Return on Common Equity (ROCE)		 -26.84% -37.45% -30.13% -22.43% -39.41% -46.66% -83.89% -37.08% -46.27% -50.70% -44.44%
Return on Equity Simple (ROE_SIMPLE)		 -21.13% -32.95% -34.43% -16.81% -28.55% -54.11% -121.86% -39.36% -48.42% -43.85% -55.79%
Net Operating Profit after Tax (NOPAT)		 -137 -108 -81 -50 -44 -39 -110 -85 -93 -91 -86
NOPAT Margin		 -1,945.22% -1,571.69% -3,422.31% -1,072.24% -597.84% -1,078.13% -1,148.09% -667.57% -1,371.08% -1,654.72% -2,389.88%
Net Nonoperating Expense Percent (NNEP)		 -3.71% -9.13% -8.88% -6.85% -11.93% -15.60% -35.71% -4.84% -14.80% -14.88% -12.85%
Return On Investment Capital (ROIC_SIMPLE)		 -18.28% -25.21% -24.73% - - - - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 549.12% 449.14% 1,153.80% 440.51% 194.88% 431.74% 202.02% 196.21% 530.19% 617.46% 575.07%
R&D to Revenue		 2,329.77% 1,714.53% 3,489.94% 1,146.23% 573.39% 1,194.29% 696.68% 754.70% 1,513.79% 1,827.94% 2,910.79%
Operating Expenses to Revenue		 2,878.89% 2,345.27% 4,989.01% 1,631.78% 954.06% 1,640.19% 1,740.13% 1,053.68% 2,058.68% 2,463.89% 3,514.11%
Earnings before Interest and Taxes (EBIT)		 -195 -155 -115 -71 -63 -55 -156 -122 -133 -130 -122
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -208 -158 -111 -71 -60 -51 -154 -116 -126 -125 -119
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.24 4.37 6.44 4.30 3.31 0.38 0.28 1.63 1.35 5.33 7.72
Price to Tangible Book Value (P/TBV)		 2.33 4.66 7.02 4.60 3.88 0.79 0.45 4.96 3.86 5.94 9.04
Price to Revenue (P/Rev)		 238.82 272.34 890.64 387.68 93.45 10.07 3.58 30.31 52.82 282.26 455.94
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 43.79 260.34 84.43 124.25 33.40 0.00 0.00 2.55 2.23 5,818.87 135.06
Enterprise Value to Revenue (EV/Rev)		 135.50 210.79 761.26 299.90 67.24 0.00 0.00 19.37 24.85 229.36 399.88
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.98 -0.96 -0.96 -0.96 -0.85 -0.73 -0.65 -0.66 -0.86 -0.98 -0.95
Leverage Ratio		 1.07 1.08 1.07 1.08 1.18 1.28 1.31 1.39 1.30 1.17 1.12
Compound Leverage Factor		 0.87 0.99 1.04 1.07 1.14 1.18 1.27 1.34 1.25 1.15 1.08
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 19.71 26.60 42.44 39.91 9.42 -11.70 -10.59 -1.47 -1.43 16.79 23.63
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 18.91 13.87 17.07 24.86 13.93 5.73 7.86 5.22 5.55 9.75 8.37
Quick Ratio		 18.38 13.69 16.41 24.71 13.81 5.62 7.71 5.09 5.44 9.62 8.23
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -153 -93 -91 -46 -30 -38 -43 -106 -168 -80 -80
Operating Cash Flow to CapEx		 -8,221.89% -5,901.60% -5,897.21% -4,984.37% -2,699.00% -6,528.13% -15,973.46% -5,588.98% -4,108.91% -2,028.04% -5,263.71%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.02 0.01 0.01 0.04 0.03 0.04 0.04 0.02 0.02 0.01
Accounts Receivable Turnover		 4.22 4.63 9.08 4.71 5.27 1.71 3.78 6.96 4.93 7.85 7.83
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.67 1.76 0.65 1.26 1.89 0.70 1.16 1.08 0.55 0.50 0.35
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 86.52 78.88 40.19 77.46 69.30 213.35 96.47 52.47 74.07 46.52 46.62
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 86.52 78.88 40.19 77.46 69.30 213.35 96.47 52.47 74.07 46.52 46.62
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 22 5.57 21 11 15 30 30 97 76 0.22 11
Invested Capital Turnover		 0.51 0.51 0.15 0.36 0.33 0.12 0.15 0.15 0.18 1.01 0.26
Increase / (Decrease) in Invested Capital		 16 -16 10 -3.71 -15 -0.40 -67 21 75 -10 -6.20
Enterprise Value (EV)		 951 1,451 1,794 1,395 499 -28 -60 247 169 1,257 1,434
Market Capitalization		 1,677 1,874 2,099 1,803 693 36 34 386 358 1,547 1,635
Book Value per Share		 $11.26 $9.08 $6.93 $8.99 $5.29 $5.83 $0.72 $1.74 $2.62 $2.94 $2.36
Tangible Book Value per Share		 $10.85 $8.51 $6.35 $8.41 $4.52 $2.81 $0.44 $0.57 $0.92 $2.64 $2.02
Total Capital		 747 429 326 419 209 94 124 236 265 290 212
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -725 -424 -305 -408 -194 -64 -94 -139 -190 -290 -201
Capital Expenditures (CapEx)		 1.92 1.82 1.76 1.22 1.50 0.71 0.47 1.79 2.75 4.88 1.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -18 -23 -5.87 -14 -11 -9.33 -7.55 -22 -29 -25 -21
Debt-free Net Working Capital (DFNWC)		 708 401 299 394 184 55 86 117 160 265 180
Net Working Capital (NWC)		 708 401 299 394 184 55 86 117 160 265 180
Net Nonoperating Expense (NNE)		 21 33 32 21 15 12 42 7.96 35 37 32
Net Nonoperating Obligations (NNO)		 -725 -424 -305 -408 -194 -64 -94 -139 -190 -290 -201
Total Depreciation and Amortization (D&A)		 -13 -3.21 3.74 -0.14 3.20 3.72 2.75 5.60 6.66 4.65 3.57
Debt-free, Cash-free Net Working Capital to Revenue		 -251.04% -334.59% -249.00% -299.70% -145.39% -261.07% -79.10% -175.84% -433.69% -459.73% -573.03%
Debt-free Net Working Capital to Revenue		 10,080.60% 5,819.67% 12,689.14% 8,477.98% 2,475.56% 1,540.86% 906.66% 918.31% 2,362.89% 4,830.22% 5,033.30%
Net Working Capital to Revenue		 10,080.60% 5,819.67% 12,689.14% 8,477.98% 2,475.56% 1,540.86% 906.66% 918.31% 2,362.89% 4,830.22% 5,033.30%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.45) ($2.92) ($2.40) ($1.64) ($2.02) ($3.51) ($14.48) ($10.80) ($19.05) ($19.65) ($19.80)
Adjusted Weighted Average Basic Shares Outstanding		 64.40M 48.45M 46.89M 42.87M 39.61M 17.57M 12.44M 9.40M 8.21M 6.58M 5.97M
Adjusted Diluted Earnings per Share		 ($2.45) ($2.92) ($2.40) ($1.64) ($2.02) ($3.51) ($14.48) ($10.80) ($19.05) ($19.65) ($19.80)
Adjusted Weighted Average Diluted Shares Outstanding		 64.40M 48.45M 46.89M 42.87M 39.61M 17.57M 12.44M 9.40M 8.21M 6.58M 5.97M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($2.02) ($3.51) ($14.48) ($10.80) ($19.05) ($19.65) ($19.80)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 66.38M 55.90M 47.21M 46.74M 29.64M 14.51M 10.44M 8.57M 6.77M 6.47M 5.96M
Normalized Net Operating Profit after Tax (NOPAT)		 -137 -99 -70 -47 -32 -37 -33 -76 -93 -91 -86
Normalized NOPAT Margin		 -1,945.22% -1,444.56% -2,976.83% -1,019.57% -427.98% -1,042.87% -343.34% -596.16% -1,371.08% -1,654.72% -2,389.88%
Pre Tax Income Margin		 -2,248.76% -2,054.76% -4,765.59% -1,520.92% -821.61% -1,423.96% -1,593.09% -920.61% -1,894.05% -2,321.11% -3,292.81%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Celldex Therapeutics

This table displays calculated financial ratios and metrics derived from Celldex Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 345.51% -71.56% 110.35% 832.09% -83.87% 156.11% 272.73% 64.42% 455.75% 384.38% 166.01%
EBITDA Growth		 -48.66% -19.42% -32.24% -49.54% -30.74% -76.85% -56.11% 4.30% -52.26% -43.22% -15.71%
EBIT Growth		 -54.50% -17.64% -26.40% -39.49% -25.06% -70.80% -48.90% 8.77% -39.62% -37.09% -33.00%
NOPAT Growth		 -54.50% -17.64% -26.40% -39.49% -25.06% -70.80% -48.90% 8.77% -39.62% -37.09% -33.00%
Net Income Growth		 -63.97% -8.74% -10.09% -17.51% -11.74% -63.50% -42.85% 15.28% -27.38% -31.46% -30.96%
EPS Growth		 -44.64% 15.48% 20.99% 16.92% 9.68% -47.37% -42.11% 15.58% -26.53% -32.56% -26.67%
Operating Cash Flow Growth		 -33.80% 0.18% -191.35% -7.84% -42.25% -49.49% 46.03% -22.26% -16.45% -49.85% -114.95%
Free Cash Flow Firm Growth		 -212.32% -213.53% -200.81% 52.46% 36.03% 40.23% 33.98% -156.69% -86.04% -180.61% -1,370.36%
Invested Capital Growth		 101.06% 289.81% 163.03% -54.34% -39.36% -73.78% -48.19% 200.15% 38.11% 89.31% 61.09%
Revenue Q/Q Growth		 -40.85% -63.18% 27.74% 1,501.28% -96.22% 172.31% 466.04% -72.29% -40.05% 296.31% 149.69%
EBITDA Q/Q Growth		 -9.51% -5.21% -10.77% -16.49% 12.03% -16.50% -25.26% -1.84% -18.99% -2.84% 23.21%
EBIT Q/Q Growth		 -11.98% -7.48% -12.54% -14.06% 14.74% -15.49% -24.20% -2.26% -16.45% -0.68% 23.90%
NOPAT Q/Q Growth		 -11.98% -7.48% -12.54% -14.06% 14.74% -15.49% -24.20% -2.26% -16.45% -0.68% 23.90%
Net Income Q/Q Growth		 -14.24% -11.80% -17.52% -9.25% 24.24% -13.19% -25.43% -3.89% -10.85% 1.11% 25.61%
EPS Q/Q Growth		 -14.08% -10.94% -18.52% 3.57% 33.33% -3.70% -24.62% -4.84% -8.77% 0.00% 25.97%
Operating Cash Flow Q/Q Growth		 -67.42% 41.31% -88.69% 27.83% -24.91% -71.29% 30.16% 4.81% -31.28% 38.16% -58.21%
Free Cash Flow Firm Q/Q Growth		 -6.27% -0.63% -190.77% -0.45% -6.68% 3.46% 54.05% -35.17% 0.32% -6.63% -78.67%
Invested Capital Q/Q Growth		 36.67% -27.36% 163.67% -23.19% 164.97% -50.99% -54.23% 2.00% 14.59% -3.16% 165.16%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -9,228.63% -4,984.77% -1,744.69% -2,012.01% -27,657.69% -1,187.29% -2,775.15% -12,540.67% -3,412.72% -1,719.40% -6,625.80%
Operating Margin		 -9,027.19% -4,768.26% -1,633.53% -1,854.16% -26,030.77% -1,152.92% -2,718.46% -12,389.93% -3,357.91% -1,728.77% -6,804.91%
EBIT Margin		 -9,027.19% -4,768.26% -1,633.53% -1,854.16% -26,030.77% -1,152.92% -2,718.46% -12,389.93% -3,357.91% -1,728.77% -6,804.91%
Profit (Net Income) Margin		 -7,740.43% -4,007.83% -1,319.99% -1,434.83% -21,030.77% -1,048.32% -2,522.08% -11,381.34% -3,036.30% -1,642.10% -6,580.84%
Tax Burden Percent		 100.00% 29.83% 0.00% 0.00% 0.00% 30.62% 0.00% 0.00% 0.00% 30.96% 100.00%
Interest Burden Percent		 85.75% 281.76% 0.00% 0.00% 0.00% 296.95% 0.00% 0.00% 0.00% 306.76% 96.71%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -2,148.84% -1,716.76% -552.73% -595.62% -5,656.50% -414.16% -498.65% -1,704.94% -352.70% -175.64% -288.47%
ROIC Less NNEP Spread (ROIC-NNEP)		 -2,147.53% -1,715.39% -551.60% -594.97% -5,655.71% -411.42% -495.29% -1,702.56% -350.69% -173.69% -286.49%
Return on Net Nonoperating Assets (RNNOA)		 2,085.59% 1,675.58% 529.55% 575.24% 5,461.86% 396.81% 467.42% 1,614.82% 329.68% 166.13% 273.46%
Return on Equity (ROE)		 -63.25% -41.18% -23.18% -20.38% -194.65% -17.35% -31.23% -90.12% -23.02% -9.52% -15.01%
Cash Return on Invested Capital (CROIC)		 -751.15% -1,118.85% -722.99% -605.58% -533.18% -689.66% -502.99% -612.66% -446.98% -558.47% -470.67%
Operating Return on Assets (OROA)		 -84.85% -53.22% -29.54% -26.89% -264.90% -19.39% -36.54% -114.85% -28.26% -10.22% -17.67%
Return on Assets (ROA)		 -72.76% -44.73% -23.87% -20.81% -214.01% -17.63% -33.90% -105.50% -25.55% -9.71% -17.09%
Return on Common Equity (ROCE)		 -63.25% -41.18% -23.18% -20.38% -194.65% -17.35% -31.23% -90.12% -23.02% -9.52% -15.01%
Return on Equity Simple (ROE_SIMPLE)		 -25.44% 0.00% -19.61% -18.46% -17.28% 0.00% -50.51% -40.76% -39.19% 0.00% -30.68%
Net Operating Profit after Tax (NOPAT)		 -44 -39 -36 -32 -28 -33 -29 -23 -23 -20 -19
NOPAT Margin		 -6,319.04% -3,337.78% -1,143.47% -1,297.91% -18,221.54% -807.04% -1,902.92% -8,672.95% -2,350.54% -1,210.14% -4,763.44%
Net Nonoperating Expense Percent (NNEP)		 -1.32% -1.37% -1.14% -0.65% -0.80% -2.74% -3.36% -2.38% -2.01% -1.95% -1.98%
Return On Investment Capital (ROIC_SIMPLE)		 -6.25% -5.25% - - - -7.77% - - - -5.98% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 1,556.83% 873.45% 315.07% 365.41% 5,835.26% 213.80% 541.92% 2,694.40% 686.66% 409.11% 1,604.67%
R&D to Revenue		 7,570.36% 3,994.81% 1,418.46% 1,588.75% 20,295.51% 736.53% 2,276.53% 9,795.52% 2,771.25% 1,419.65% 5,300.25%
Operating Expenses to Revenue		 9,127.19% 4,868.26% 1,733.53% 1,954.16% 26,130.77% 1,252.92% 2,818.46% 12,489.93% 3,457.91% 1,828.77% 6,904.91%
Earnings before Interest and Taxes (EBIT)		 -63 -56 -52 -46 -41 -48 -41 -33 -32 -28 -28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -64 -59 -56 -50 -43 -49 -42 -34 -33 -28 -27
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.71 2.24 2.87 3.00 2.37 4.37 5.27 5.78 5.61 6.44 3.81
Price to Tangible Book Value (P/TBV)		 1.78 2.33 2.97 3.10 2.44 4.66 5.92 6.40 6.16 7.02 4.13
Price to Revenue (P/Rev)		 159.39 238.82 225.85 293.83 326.69 272.34 297.97 492.56 539.21 890.64 1,220.77
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 17.90 43.79 50.06 144.33 78.54 260.34 93.69 54.37 58.31 84.43 45.17
Enterprise Value to Revenue (EV/Rev)		 70.32 135.50 150.07 197.19 191.01 210.79 244.05 414.92 450.83 761.26 920.43
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.97 -0.98 -0.96 -0.97 -0.97 -0.96 -0.94 -0.95 -0.94 -0.96 -0.95
Leverage Ratio		 1.04 1.07 1.07 1.05 1.05 1.08 1.10 1.09 1.07 1.07 1.06
Compound Leverage Factor		 0.89 3.01 0.00 0.00 0.00 3.22 0.00 0.00 0.00 3.28 1.03
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 17.57 20.29 34.60 44.36 38.03 27.36 16.97 38.67 41.94 43.25 29.26
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 21.67 18.91 24.27 29.36 31.77 13.87 8.84 16.93 19.03 17.07 20.54
Quick Ratio		 21.06 18.38 23.58 29.06 31.44 13.69 8.46 16.16 18.38 16.41 19.87
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -59 -55 -55 -19 -19 -18 -18 -40 -29 -30 -28
Operating Cash Flow to CapEx		 -20,517.74% -4,295.77% -10,153.58% -10,703.28% -11,813.37% -4,884.83% -12,097.45% -6,633.17% -4,883.59% -9,260.43% -10,200.58%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.00
Accounts Receivable Turnover		 4.05 4.22 18.07 10.05 3.05 4.63 19.80 30.28 4.05 9.08 5.58
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.75 1.67 2.38 2.13 1.51 1.76 1.10 0.85 0.84 0.65 0.30
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 90.18 86.52 20.20 36.32 119.77 78.88 18.44 12.05 90.21 40.19 65.41
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 90.18 86.52 20.20 36.32 119.77 78.88 18.44 12.05 90.21 40.19 65.41
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 30 22 30 11 15 5.57 11 25 24 21 22
Invested Capital Turnover		 0.34 0.51 0.48 0.46 0.31 0.51 0.26 0.20 0.15 0.15 0.06
Increase / (Decrease) in Invested Capital		 15 16 19 -13 -9.59 -16 -11 17 6.72 10 8.32
Enterprise Value (EV)		 532 951 1,497 1,637 1,160 1,451 1,065 1,351 1,420 1,794 991
Market Capitalization		 1,205 1,677 2,253 2,439 1,984 1,874 1,301 1,603 1,699 2,099 1,315
Book Value per Share		 $10.59 $11.26 $11.86 $12.34 $14.24 $9.08 $5.22 $5.87 $6.41 $6.93 $7.39
Tangible Book Value per Share		 $10.18 $10.85 $11.45 $11.93 $13.78 $8.51 $4.65 $5.30 $5.84 $6.35 $6.80
Total Capital		 703 747 786 814 839 429 247 278 303 326 345
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -673 -725 -756 -802 -824 -424 -235 -253 -278 -305 -323
Capital Expenditures (CapEx)		 0.27 0.76 0.55 0.27 0.34 0.67 0.16 0.41 0.59 0.24 0.35
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -18 -9.25 -18 -15 -23 -17 -3.52 -4.01 -5.87 -5.16
Debt-free Net Working Capital (DFNWC)		 662 708 747 784 809 401 218 249 274 299 318
Net Working Capital (NWC)		 662 708 747 784 809 401 218 249 274 299 318
Net Nonoperating Expense (NNE)		 9.88 7.87 5.63 3.42 4.38 9.97 9.39 7.26 6.63 6.97 7.40
Net Nonoperating Obligations (NNO)		 -673 -725 -756 -802 -824 -424 -235 -253 -278 -305 -323
Total Depreciation and Amortization (D&A)		 -1.40 -2.54 -3.55 -3.94 -2.54 -1.42 -0.86 -0.40 -0.53 0.15 0.73
Debt-free, Cash-free Net Working Capital to Revenue		 -152.82% -251.04% -92.72% -216.82% -243.96% -334.59% -395.21% -108.23% -127.27% -249.00% -479.02%
Debt-free Net Working Capital to Revenue		 8,754.32% 10,080.60% 7,485.46% 9,447.33% 13,324.00% 5,819.67% 4,996.49% 7,655.12% 8,710.41% 12,689.14% 29,555.43%
Net Working Capital to Revenue		 8,754.32% 10,080.60% 7,485.46% 9,447.33% 13,324.00% 5,819.67% 4,996.49% 7,655.12% 8,710.41% 12,689.14% 29,555.43%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.81) ($0.71) ($0.64) ($0.54) ($0.56) ($0.84) ($0.81) ($0.65) ($0.62) ($0.57) ($0.57)
Adjusted Weighted Average Basic Shares Outstanding		 66.38M 64.40M 66.29M 66.02M 58.87M 48.45M 47.26M 47.25M 47.21M 46.89M 46.92M
Adjusted Diluted Earnings per Share		 ($0.81) ($0.71) ($0.64) ($0.54) ($0.56) ($0.84) ($0.81) ($0.65) ($0.62) ($0.57) ($0.57)
Adjusted Weighted Average Diluted Shares Outstanding		 66.38M 64.40M 66.29M 66.02M 58.87M 48.45M 47.26M 47.25M 47.21M 46.89M 46.92M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 66.39M 66.38M 66.34M 66.29M 65.91M 55.90M 47.26M 47.26M 47.25M 47.21M 47.10M
Normalized Net Operating Profit after Tax (NOPAT)		 -44 -39 -36 -32 -28 -33 -29 -23 -23 -20 -19
Normalized NOPAT Margin		 -6,319.04% -3,337.78% -1,143.47% -1,297.91% -18,221.54% -807.04% -1,902.92% -8,672.95% -2,350.54% -1,210.14% -4,763.44%
Pre Tax Income Margin		 -7,740.43% -13,435.15% 0.00% 0.00% 0.00% -3,423.60% 0.00% 0.00% 0.00% -5,303.22% -6,580.84%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Celldex Therapeutics' Financials

When does Celldex Therapeutics's financial year end?

According to the most recent income statement we have on file, Celldex Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Celldex Therapeutics' net income changed over the last 10 years?

In the past 10 years, Celldex Therapeutics' net income has ranged from -$157.86 million in 2024 to -$50.88 million in 2019, and is currently -$157.86 million as of their latest financial filing in 2024. Check out Celldex Therapeutics' forecast to explore projected trends and price targets.

What is Celldex Therapeutics's operating income?
Celldex Therapeutics's total operating income in 2024 was -$195.08 million, based on the following breakdown:
  • Total Gross Profit: $7.02 million
  • Total Operating Expenses: $202.10 million
How has Celldex Therapeutics revenue changed over the last 10 years?

Over the last 10 years, Celldex Therapeutics' total revenue changed from $3.59 million in 2014 to $7.02 million in 2024, a change of 95.8%.

How much debt does Celldex Therapeutics have?

Celldex Therapeutics' total liabilities were at $45.34 million at the end of 2024, a 24.4% increase from 2023, and a 24.7% increase since 2014.

How much cash does Celldex Therapeutics have?

In the past 10 years, Celldex Therapeutics' cash and equivalents has ranged from $11.23 million in 2019 to $72.11 million in 2015, and is currently $28.36 million as of their latest financial filing in 2024.

How has Celldex Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Celldex Therapeutics' book value per share changed from 2.36 in 2014 to 11.26 in 2024, a change of 376.6%.


Related Companies

This page (NASDAQ:CLDX) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored